Q32 BIO INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants with IgAN, LN or C3G
Phase 2
Recruiting
- Conditions
- Lupus Nephritis (LN)C3 (Complement Component 3) GlomerulopathyIgA Nephropathy
- Interventions
- Drug: ADX-097
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06419205
- Locations
- 🇺🇸
Denver, Denver, Colorado, United States
🇺🇸Minneapolis, Minneapolis, Minnesota, United States
🇺🇸Las Vegas, Las Vegas, Nevada, United States
Randomized, Double-Blind, Placebo-Controlled Phase 2a, Proof-of-Concept Trial of ADX-914 Phase 2a Trial for the Treatment of Severe Alopecia Areata
Phase 2
Active, not recruiting
- Conditions
- Alopecia Areata
- Interventions
- Drug: ADX-914Drug: Placebo
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06018428
- Locations
- 🇺🇸
Mayfield Heights, Ohio, Mayfield Heights, Ohio, United States
🇺🇸Scottsdale, Arizona, Scottsdale, Arizona, United States
🇺🇸Fayetteville, Arkansas, Fayetteville, Arkansas, United States
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
Phase 2
Active, not recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: PlaceboDrug: ADX-914
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05509023
- Locations
- 🇺🇸
JBR Clinical Research, Salt Lake City, Utah, United States
🇺🇸Dermatology of Seattle & Bellevue, Seattle, Washington, United States
🇺🇸Dermatology Specialists of Spokane, Spokane, Washington, United States
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Safety Issues
- Interventions
- Drug: ADX-914Drug: Placebo
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Q32 Bio Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT04485481
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath